BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

DiaGenic ASA: Annual General Meeting Held


5/23/2013 10:46:52 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

OSLO, Norway--(BUSINESS WIRE)--Regulatory News: The annual general meeting of DiaGenic ASA (OSE:DIAG) was held on 23 May 2013.

All proposals set out in the notice to the general meeting were approved.

In accordance with the recommendation from the Nomination Committee Hanne Skaarberg Holen was elected as Chairman of the board, and Patrik Dahlen, Ulrica Slåne and Tom Pike were elected as members of the board.

Leif Eriksrød (Alfred Berg Kapitalforvaltning) was elected as Chair of the Nomination Committee, and Andreas Lorentzen (Storebrand Kapitalforvaltning) and Inga Lise Lien Moldestad (Holberg Fondene) were elected as members of the Nomination Committee.

The minutes from the annual general meeting will be available at:

www.newsweb.no and www.diagenic.com

About DiaGenic ASA

DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com

This information was brought to you by Cision http://news.cision.com

Contacts

DiaGenic ASA

Paul de Potocki

CEO

Telephone: + 47 2324 8950

or

Ruben Ekbråten

CFO

Telephone: +47 2324 8950



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->